BioTissue reports positive Phase 2 dry eye results for TTAX03

BioTissue will present Phase 2 data on TTAX03 at the American Academy of Ophthalmology annual meeting in New Orleans. The investigational biologic showed a favorable safety profile, with the highest dose delivering the strongest signal across symptoms and corneal staining in adults with mild to moderate dry eye disease.

Why it matters: - Dry eye disease affects comfort, vision and corneal health, and treatment response can vary widely from patient to patient. - A favorable safety profile and a dose-related efficacy signal could help shape the next phase of development for TTAX03. - The data may inform whether an investigational biologic derived from human birth tissue can become a new option for mild to moderate dry eye disease.

What happened: - BioTissue will present Phase 2 results for TTAX03 at the American Academy of Ophthalmology annual meeting in New Orleans, which runs Oct. 9-12. - The study was prospective, randomized, controlled, double-masked and multicenter. - Researchers enrolled 74 adults with mild to moderate dry eye disease. - Patients were randomized 1:1:1:1 to three TTAX03 concentrations or saline control. - Each treatment was administered under a bandage contact lens for five days. - The primary objective was to evaluate ocular and general safety through 12 weeks.

The details: - No treatment-related serious adverse events were reported in any study group. - The highest TTAX03 dose produced the greatest improvement in overall symptoms and eye dryness on the visual analogue scale. - The highest dose also showed the highest incidence of complete resolution of corneal staining. - Best-corrected visual acuity changed by Day 85 in the highest-dose group. - The findings suggest TTAX03 appears safe, with the strongest improvement signal at the highest dose in patients with mild to moderate dry eye disease. - Additional research will be needed to confirm efficacy and define the right dose and treatment regimen. - Presentation details and the complete conference program are available in the AAO conference program.

Between the lines: - The study’s design supports a cleaner read on both safety and early efficacy than an uncontrolled trial would provide. - The dose-response pattern matters because it can guide future trial design and help identify whether benefit increases with higher exposure. - The focus on symptoms and corneal staining suggests the program is targeting both how patients feel and measurable eye-surface damage. - BioTissue framed the work as part of its broader development of regenerative products derived from human birth and placental tissue.

What's next: - BioTissue is likely to use the Phase 2 findings to inform additional efficacy testing and dose selection. - Further studies will need to establish whether the early signal holds up in larger trials and over longer follow-up. - Conference presentation at AAO may bring more attention to TTAX03 and the broader dry eye pipeline.

The bottom line: - TTAX03 cleared an early safety hurdle and showed its best results at the highest dose, but more data are needed before the therapy’s role in dry eye care is clear.